Clinical trials often face a significant hurdle: recruiting and retaining a diverse participant pool. Traditional trial models, predominantly located in urban medical centers and research facilities, often unintentionally exclude minority populations due to accessibility and logistical barriers. This can lead to skewed data and less effective treatments.
The Rise of Community-Based Research
Digitization and the use of decentralized components, such as wearable technology and electronic patient-reported outcome (ePRO) devices, are transforming the clinical trial landscape. According to GlobalData’s State of the Biopharmaceutical Industry 2024 Report (Mid-Year Update), 7.58% of ongoing clinical trials are now incorporating decentralized elements. These innovative methods enhance the patient experience and improve accessibility and retention rates. However, to truly make trials inclusive, there’s a need for more than just technological advancements.
Deploying community-based research sites, such as mobile units located within existing healthcare infrastructure like health centers, hospitals, and pharmacies, can make a significant difference. This more personalized approach ensures trials reach and retain participants from diverse backgrounds.
Debunking Myths about Community-Based Research
Community-based research methods are often deployed to offer participants greater flexibility and convenience in their involvement. While this model is gaining momentum, several misconceptions persist. Let’s address five common myths and understand the true benefits:
1. Recruitment and Retention Are More Difficult
Contrary to the misconception, trials with community-based research sites often experience improved recruitment and retention rates. By conducting trials closer to home, the travel burden on patients is reduced, making participation more accessible.
Integrated community engagement establishes connections with residents and local organizations. By actively participating in local events and activities, community-based research providers build trust and credibility, which are crucial for long-term collaboration.
EmVenio, a PCM Trials company, actively combats low participant retention and limited diversity seen in traditional trials. By strategically placing sites within local communities, EmVenio ensures trials are more accessible and inclusive. This approach leads to higher participant engagement and a more diverse and representative sample.
EmVenio boasts over 50% of their trial participants coming from minority populations, surpassing the industry average of 20%. Additionally, their retention rate of 92% is significantly higher than the industry average of 70%, showcasing how community-based research can remove participation barriers.
2. Decentralized Trials Lack Regulatory Oversight
Another common misconception is that community-based research sites, particularly for decentralized trials, operate with less